Trial Profile
Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Axicabtagene ciloleucel (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
- 29 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 29 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 29 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.